All In Biotech

Drug Trial Radar · NCT06188325

A Study to Evaluate Pharmacokinetic Parameters of Eliglustat in Healthy Volunteers Who Are CYP2D6 Extensive or Poor Metabolizers

A Randomized, Three-Period Crossover Study of Single and Repeated Doses for Three Different Strengths of Eliglustat in Healthy Adult, CYP2D6 Extensive and Poor Metabolizers

Last checked: Nov 20, 2026Latest source record: Jan 10, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

18

Actual

Start

Jan 1, 2018

Primary completion

Mar 26, 2018

Study completion Mar 26, 2018

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Jan 3, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary objective of the study is to evaluate dose proportionality and pharmacokinetics for three different dose levels of eliglustat after single and repeated administration.

Conditions

  • Gaucher's Disease

Interventions

  • EliglustatDrug

    Pharmaceutical form:Capsule-Route of administration:Oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pharmacokinetic (PK) parameter: CmaxTime frame: Multiple timepoints up to Day 35
  2. Pharmacokinetic (PK) parameter: tmaxTime frame: Multiple timepoints up to Day 35
  3. Pharmacokinetic (PK) parameter: AUC0-TTime frame: Multiple timepoints up to Day 35
  4. Pharmacokinetic (PK) parameter: AUCTime frame: Multiple timepoints up to Day 35

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • M.D.Covance Clinical Research Unit 1341 W

    Dallas, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.